108 related articles for article (PubMed ID: 19318330)
1. [Position statement of the (Hungarian) College of Oncology and Radiotherapy regarding the financing of Tyverb (lapatinib) based on individual discretionary compassionate care].
Pikó B;
Magy Onkol; 2009 Mar; 53(1):77-9. PubMed ID: 19318330
[No Abstract] [Full Text] [Related]
2. Lapatinib-associated toxicity and practical management recommendations.
Moy B; Goss PE
Oncologist; 2007 Jul; 12(7):756-65. PubMed ID: 17673607
[TBL] [Abstract][Full Text] [Related]
3. [Advances in research on treatment of breast cancer with lapatinib].
Ma CD; Shen KW; Shen ZZ
Zhonghua Zhong Liu Za Zhi; 2008 May; 30(5):321-4. PubMed ID: 18953827
[No Abstract] [Full Text] [Related]
4. Lapatinib study supports cancer stem cell hypothesis, encourages industry research.
Schmidt C
J Natl Cancer Inst; 2008 May; 100(10):694-5. PubMed ID: 18477795
[No Abstract] [Full Text] [Related]
5. TEACH: Tykerb evaluation after chemotherapy.
Moy B; Goss PE
Clin Breast Cancer; 2007 Feb; 7(6):489-92. PubMed ID: 17386127
[No Abstract] [Full Text] [Related]
6. Lapatinib.
Moy B; Kirkpatrick P; Kar S; Goss P
Nat Rev Drug Discov; 2007 Jun; 6(6):431-2. PubMed ID: 17633789
[No Abstract] [Full Text] [Related]
7. [Position statement of the (Hungarian) College of Oncology and Radiotherapy regarding the health insurance reimbursement for Emend(aprepitant)].
Pikó B;
Magy Onkol; 2009 Mar; 53(1):81-2. PubMed ID: 19318331
[No Abstract] [Full Text] [Related]
8. [Position statement of the Hungarian Radiotherapy and Oncology College on the insurance coverage of Ratiograstim (biocompatible filgrastim)].
Pikó B;
Magy Onkol; 2009 Jun; 53(2):177-8. PubMed ID: 19581185
[No Abstract] [Full Text] [Related]
9. Closing in on a cure.
Healy B
US News World Rep; 2006 Oct; 141(15):67. PubMed ID: 17432437
[No Abstract] [Full Text] [Related]
10. [Position statement of the Hungarian Radiotherapy and Oncology College on the insurance coverage of Vectibix (panitumumab)].
Pikó B;
Magy Onkol; 2009 Jun; 53(2):175-6. PubMed ID: 19581184
[No Abstract] [Full Text] [Related]
11. Neratinib (Nerlynx) for HER2-positive breast cancer.
Med Lett Drugs Ther; 2018 Jan; 60(1539):23. PubMed ID: 29364199
[No Abstract] [Full Text] [Related]
12. Lapatinib: new drug. For some women with metastatic breast cancer.
Prescrire Int; 2009 Feb; 18(99):9. PubMed ID: 19382400
[No Abstract] [Full Text] [Related]
13. Acute paronychia caused by lapatinib therapy.
Rigopoulos D; Gregoriou S; Belyayeva Y; Larios G; Gkouvi A; Katsambas A
Clin Exp Dermatol; 2009 Jan; 34(1):94-5. PubMed ID: 19076807
[No Abstract] [Full Text] [Related]
14. Genotypic intratumoral heterogeneity in breast carcinoma with HER2/neu amplification: evaluation according to ASCO/CAP criteria.
Brunelli M; Manfrin E; Martignoni G; Miller K; Remo A; Reghellin D; Bersani S; Gobbo S; Eccher A; Chilosi M; Bonetti F
Am J Clin Pathol; 2009 May; 131(5):678-82. PubMed ID: 19369627
[TBL] [Abstract][Full Text] [Related]
15. Quo vadis with targeted drugs in the 21st century?
Bergh J
J Clin Oncol; 2009 Jan; 27(1):2-5. PubMed ID: 19047306
[No Abstract] [Full Text] [Related]
16. The role of topoisomerase IIalpha and HER-2 in predicting sensitivity to anthracyclines in breast cancer patients.
Oakman C; Moretti E; Galardi F; Santarpia L; Di Leo A
Cancer Treat Rev; 2009 Dec; 35(8):662-7. PubMed ID: 19758759
[TBL] [Abstract][Full Text] [Related]
17. Many new cancer drugs in the United Kingdom are facing negative NICE rulings.
Low E;
J Clin Oncol; 2007 Jun; 25(18):2635-6; author reply 2637-8. PubMed ID: 17577049
[No Abstract] [Full Text] [Related]
18. The impact of patient advocacy: the case of innovative breast cancer drug reimbursement.
Nahuis R; Boon WP
Sociol Health Illn; 2011 Jan; 33(1):1-15. PubMed ID: 21039620
[TBL] [Abstract][Full Text] [Related]
19. American Society of Clinical Oncology guidance statement: the cost of cancer care.
Meropol NJ; Schrag D; Smith TJ; Mulvey TM; Langdon RM; Blum D; Ubel PA; Schnipper LE;
J Clin Oncol; 2009 Aug; 27(23):3868-74. PubMed ID: 19581533
[TBL] [Abstract][Full Text] [Related]
20. Upregulation of lactate dehydrogenase A by ErbB2 through heat shock factor 1 promotes breast cancer cell glycolysis and growth.
Zhao YH; Zhou M; Liu H; Ding Y; Khong HT; Yu D; Fodstad O; Tan M
Oncogene; 2009 Oct; 28(42):3689-701. PubMed ID: 19668225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
